Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 ...

Its solution is a licensing deal with Chinese biotech LaNova Medicines for LM-299, which consists of an anti-VEGF antibody joined to the functional parts of a pair of anti-PD-1 antibodies.

Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Combining PORT-6 and PORT-7 for a More Comprehensive Immunotherapy Approach ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced it will present preclinical ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

Summit Therapeutics (NASDAQ:SMMT) stock spikes as Citi upgrades the company, citing its lead asset ivonescimab, developed ...

BeyondSpring , with significant clinical progress for our first-in-class agent Plinabulin and strategic advancements for SEED Therapeutics, which Be ...

Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the ...